Literature DB >> 33923139

Serum Osteoprotegerin and Carotid Intima-Media Thickness Are Related to High Arterial Stiffness in Heart Failure with Reduced Ejection Fraction.

Lajos Fehérvári1,2, Attila Frigy1,2, Lóránd Kocsis1, István Adorján Szabó1,2, Timea Magdolna Szabo1,3, Melinda Urkon3, Zita Jakó4, Előd Ernő Nagy3,5.   

Abstract

Arterial stiffness (AS) is a complex vascular phenomenon with consequences for central hemodynamics and left-ventricular performance. Circulating biomarkers have been associated with AS; however, their value in heart failure is poorly characterized. Our aim was to evaluate the clinical and biomarker correlates of AS in the setting of heart failure with reduced ejection fraction (HFrEF). In 78 hospitalized, hemodynamically stable patients (20 women, 58 men, mean age 65.8 ± 1.41 years) with HFrEF, AS was measured using aortic pulse wave velocity (PWV). Serum OPG, RANKL, sclerostin, and DKK-1 were determined, and the relationships between the clinical variables, vascular-calcification-related biomarkers, and PWV were evaluated by correlation analysis and linear and logistic regression models. OPG and the OPG/RANKL ratio were significantly higher in the group of patients (n = 37, 47.4%) with increased PWV (>10 m/s). PWV was positively correlated with age, left-ventricular ejection fraction, and carotid intima-media thickness (cIMT), and negatively correlated with the glomerular filtration rate. OPG and cIMT were significantly associated with PWV in the logistic regression models when adjusted for hypertension, EF, and the presence of atherosclerotic manifestations. Elevated serum OPG, together with cIMT, were significantly related to increased AS in the setting of HFrEF.

Entities:  

Keywords:  arterial stiffness; calcification biomarkers; heart failure; osteoprotegerin; pulse wave velocity

Year:  2021        PMID: 33923139     DOI: 10.3390/diagnostics11050764

Source DB:  PubMed          Journal:  Diagnostics (Basel)        ISSN: 2075-4418


  56 in total

1.  Bone Like Arterial Calcification in Femoral Atherosclerotic Lesions: Prevalence and Role of Osteoprotegerin and Pericytes.

Authors:  J-M Davaine; T Quillard; M Chatelais; F Guilbaud; R Brion; B Guyomarch; M Á Brennan; D Heymann; M-F Heymann; Y Gouëffic
Journal:  Eur J Vasc Endovasc Surg       Date:  2015-11-30       Impact factor: 7.069

Review 2.  Relation between serum osteoprotegerin and carotid intima media thickness in a general population - the Tromsø Study.

Authors:  A Vik; E B Mathiesen; J Brox; T Wilsgaard; I Njølstad; L Jørgensen; J-B Hansen
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

Review 3.  The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases.

Authors:  Luc Rochette; Alexandre Meloux; Eve Rigal; Marianne Zeller; Yves Cottin; Catherine Vergely
Journal:  Pharmacol Ther       Date:  2017-09-01       Impact factor: 12.310

Review 4.  Vascular calcification: an update on mechanisms and challenges in treatment.

Authors:  Meiting Wu; Cameron Rementer; Cecilia M Giachelli
Journal:  Calcif Tissue Int       Date:  2013-03-01       Impact factor: 4.333

5.  Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers.

Authors:  Dhakshinamurthy Vijay Anand; Eric Lim; Daniel Darko; Paul Bassett; David Hopkins; David Lipkin; Roger Corder; Avijit Lahiri
Journal:  J Am Coll Cardiol       Date:  2007-11-19       Impact factor: 24.094

6.  Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients.

Authors:  Yueh-Ting Lee; Hwee-Yeong Ng; Terry Ting-Yu Chiu; Lung-Chih Li; Sung-Nan Pei; Wei-Hung Kuo; Chien-Te Lee
Journal:  Clin Chim Acta       Date:  2015-10-30       Impact factor: 3.786

Review 7.  Osteoprotegerin, vascular calcification and atherosclerosis.

Authors:  Ann Van Campenhout; Jonathan Golledge
Journal:  Atherosclerosis       Date:  2008-10-09       Impact factor: 5.162

8.  Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis.

Authors:  Smriti Murali Krishna; Sai-Wang Seto; Roby J Jose; Jiaze Li; Susan K Morton; Erik Biros; Yutang Wang; Vianne Nsengiyumva; Jan H N Lindeman; Gabriela G Loots; Catherine M Rush; Jeffrey M Craig; Jonathan Golledge
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-12-22       Impact factor: 8.311

Review 9.  The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox

Authors:  Flora Özkalaycı; Öykü Gülmez; Betül Uğur-Altun; Seithikurippu Ratnas Pandi-Perumal; Armağan Altun
Journal:  Balkan Med J       Date:  2018-04-24       Impact factor: 2.021

10.  Correlations between Vascular Stiffness Indicators, OPG, and 25-OH Vitamin D3 Status in Heart Failure Patients.

Authors:  Florina Nicoleta Buleu; Constantin Tudor Luca; Anca Tudor; Marius Badalica-Petrescu; Alexandru Caraba; Ana Pah; Doina Georgescu; Ruxandra Christodorescu; Simona Dragan
Journal:  Medicina (Kaunas)       Date:  2019-06-25       Impact factor: 2.430

View more
  2 in total

1.  Elevated Serum Cystatin C and Decreased Cathepsin S/Cystatin C Ratio Are Associated with Severe Peripheral Arterial Disease and Polyvascular Involvement.

Authors:  Előd Ernő Nagy; Attila Puskás; Piroska Kelemen; Katalin Makó; Zoltán Brassai; Jolán Hársfalvi; Attila Frigy
Journal:  Diagnostics (Basel)       Date:  2022-03-28

Review 2.  Targeting Mediators of Inflammation in Heart Failure: A Short Synthesis of Experimental and Clinical Results.

Authors:  Timea Magdolna Szabo; Attila Frigy; Előd Ernő Nagy
Journal:  Int J Mol Sci       Date:  2021-12-02       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.